《临床肿瘤学杂志》中的卫生经济学以及与辅助性曲妥珠单抗相关的间接成本和效益评估 - Suppr | 超能文献

Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.

作者信息

de Lima Lopes Gilberto, Gluck Stefan

出版信息

J Clin Oncol. 2007 Aug 1;25(22):3382-3; author reply 3383. doi: 10.1200/JCO.2007.12.3760.

DOI:10.1200/JCO.2007.12.3760

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.《临床肿瘤学杂志》中的卫生经济学以及与辅助性曲妥珠单抗相关的间接成本和效益评估

J Clin Oncol. 2007 Aug 1;25(22):3382-3; author reply 3383. doi: 10.1200/JCO.2007.12.3760.

2

Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?辅助性乳腺癌曲妥珠单抗治疗所带来的巨大益处是否能抵消其高昂成本？

J Clin Oncol. 2007 Feb 20;25(6):611-3. doi: 10.1200/JCO.2006.09.3542.

3

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.曲妥珠单抗在辅助治疗HER2阳性乳腺癌中的成本效益分析。

Cancer. 2007 Aug 1;110(3):489-98. doi: 10.1002/cncr.22806.

4

[Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].[曲妥珠单抗治疗葡萄牙早期乳腺癌患者的成本效益分析]

Acta Med Port. 2010 May-Jun;23(3):475-82. Epub 2010 Jun 14.

5

Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.曲妥珠单抗用于早期乳腺癌：比利时的成本效益分析

Health Policy. 2008 Aug;87(2):146-59. doi: 10.1016/j.healthpol.2007.11.003. Epub 2008 Mar 4.

6

Trastuzumab in breast cancer.曲妥珠单抗在乳腺癌中的应用

N Engl J Med. 2006 Feb 9;354(6):640-4; author reply 640-4.

7

Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.奖励价值创造以促进肿瘤学创新：考虑全球产品生命周期的重要性。

Oncologist. 2010;15 Suppl 1:49-57. doi: 10.1634/theoncologist.2010-S1-49.

8

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.曲妥珠单抗辅助治疗人表皮生长因子受体2阳性乳腺癌的成本效益

J Clin Oncol. 2007 Feb 20;25(6):625-33. doi: 10.1200/JCO.2006.06.4220.

9

[Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].[曲妥珠单抗辅助治疗HER2阳性早期乳腺癌的成本/效果分析]

Bull Cancer. 2007 Jul;94(7):711-20.

10

Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.HER2/Neu阳性乳腺癌序贯辅助曲妥珠单抗治疗的成本效用

Value Health. 2009 Jul-Aug;12(5):637-40. doi: 10.1111/j.1524-4733.2009.00564.x. Epub 2009 May 15.

引用本文的文献

1

Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore.新加坡曲妥珠单抗治疗早期 HER2neu 过表达乳腺癌患者的社会成本和效益。

BMC Cancer. 2011 May 18;11:178. doi: 10.1186/1471-2407-11-178.

2

Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.曲妥珠单抗：早期乳腺癌应用的药物经济学综述

Pharmacoeconomics. 2008;26(8):699-719. doi: 10.2165/00019053-200826080-00006.